0.64
+0.36%
Close of 9 Nov 2026, in USD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Aldeyra Therapeutics
From its filings with the US Securities and Exchange Commission
Aldeyra Therapeutics is based in Concord, Massachusetts and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker ALDX. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported a net loss of $33.8m. At that date it held total assets of $72.1m and shareholders' equity of $44.3m.
Aldeyra Therapeutics is a biotechnology company devoted to discovering innovative therapies designed to treat immune-mediated diseases. Our approach is to develop pharmaceuticals that modulate protein systems, instead of directly inhibiting or activating single protein targets, with the goal of optimizing multiple pathways at once while minimizing toxicity. Our product candidates include RASP (reactive aldehyde species) modulators ADX-248, ADX-246, and chemically related molecules for the potential treatment of systemic and retinal immune-mediated diseases. Our late-stage product candidates are reproxalap, a RASP modulator for the potential treatment of dry eye disease and allergic conjunctivitis, and ADX-2191, a novel formulation of intravitreal methotrexate for the potential treatment of primary vitreoretinal lymphoma and retinitis pigmentosa.
Quoted from its 10-K, filed 27 Feb 2026. Read the filing on SEC.gov ↗
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 2 May 2014
- Employees
- 8
- Website
- aldeyra.com ↗
- Head office
- 23 BRADFORD STREET, CONCORD, MA, 01742
- Incorporated in
- DE
- Classification
- Pharmaceutical Preparations
- Filer status
- Non-accelerated filer<br>Smaller reporting company
Leadership
Pay as last reported
- Dr. Richard DouglasIndependent Chairman of the Board$217,449
- Dr. Todd BradyPresident, Chief Executive Officer, Director, since 2005$3.9m
- Mr. Michael AlfieriPrincipal Financial Officer and Principal Accounting Officer$111,650
- Dr. Stephen MachathaChief Development Officer$1.7m
- Dr. Ben BronsteinIndependent Director$186,401
- Mr. William ClarkIndependent Director
- Mr. Martin JoyceIndependent Director$191,576
- Ms. Nancy Miller-RichIndependent Director$170,540
- Dr. Gary PhillipsIndependent Director$190,018
- Dr. Neal WalkerIndependent Director$170,540
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 42
- Environment
- 42
- Social
- 59
- Governance
- 26
- Carbon reduction policy
- No
- Human rights policy
- Yes
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Aldeyra Therapeutics Inc has several key strengths that contribute to its success:
Weaknesses
- Aldeyra Therapeutics Inc faces certain weaknesses that could hinder its performance:
Opportunities
- Aldeyra Therapeutics Inc can leverage the following opportunities to grow and expand:
Threats
- Aldeyra Therapeutics Inc should be aware of the following threats that may impact its operations:
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.